UNSPSC 51432207: Dihydralazine tartrate

This classification denotes an antihypertensive agent and hydrazine C8H10N6.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J9CB6K1N70, chemically known as 1,4-phthalazinedione, 2,3-dihydro-, dihydrazone, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as dihydralazine tartrate, which bears US NIH Compound Identifier 56842459. European Medicines Agency schedules Dihydralazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01703MIG.

Most nations, for tariff and trade purposes, schedule dihydralazine tartrate under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)C(NNC2NN)NN.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51432207 Dihydralazine tartrate is a Commodity code covering specific pharmaceutical active ingredients and finished-dose medications procured by state and local health and public-safety agencies. State and local governments buy this code primarily as finished medications for emergency medical services and public health programs — typically in sealed competitive bids tied to emergency responder supply chains, pharmacy benefit management programs, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The Tampa Fire Rescue procurement exemplifies the scope: the City of Tampa's Purchasing Department solicited four advanced life support medications (including epinephrine, adenosine, diltiazem, and labetalol) as sealed-bid goods with firm pricing, specified minimum shelf life and expiration-date requirements, and ten-day delivery timelines. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing vehicles that coordinate procurement across state and local members. The issuing-body mix spans city purchasing departments (Tampa), state health commissions (Texas HHS), and statewide cooperative alliances (Minnesota MMCAP).

Recent activity appears concentrated in the South and Midwest. The Tampa Fire Rescue bid (Solicitation 26P00188, IFB, due April 8, 2026, estimated contract value $40,000) represents municipal emergency-services procurement in Florida; the Texas HHS RFI (HHS0017013, RFI, response deadline April 3, 2026) signals state-level interest in direct-to-manufacturer pharmacy programs; and the Minnesota MMCAP RFP (S1070000015802, RFP, due March 26, 2026) reflects multistate cooperative contracting for generic pharmaceuticals and OTC products across Minnesota, Oregon, and participating members. The MMCAP vehicle notably requires vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), demonstrate cGMP and DSCSA compliance, and accept a 3 percent administrative fee on contract purchases. Tampa's procurement includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount capped at $10,000.